Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ EGRX opened at $0.88 on Friday. The company’s 50 day moving average price is $3.78 and its 200-day moving average price is $4.38. Eagle Pharmaceuticals has a 52-week low of $0.10 and a 52-week high of $14.78. The company has a market capitalization of $11.36 million, a P/E ratio of 0.74 and a beta of 0.51.

Institutional Trading of Eagle Pharmaceuticals

A number of large investors have recently bought and sold shares of EGRX. AIGH Capital Management LLC boosted its position in shares of Eagle Pharmaceuticals by 2.1% during the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after purchasing an additional 25,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after buying an additional 2,630 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock worth $1,005,000 after buying an additional 100,470 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $971,000. Finally, DGS Capital Management LLC increased its stake in shares of Eagle Pharmaceuticals by 442.5% in the 1st quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after acquiring an additional 50,525 shares in the last quarter. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.